Thu Mar 20 16:41:32 UTC 2025: ## Lilly’s Mounjaro Diabetes and Weight-Loss Drug Launches in India

**NEW DELHI** – Eli Lilly and Company has launched Mounjaro (tirzepatide), a groundbreaking diabetes and weight-loss drug, in India. The drug, approved by the Central Drugs Standard Control Organisation (CDSCO), is a once-weekly injection available in 2.5mg (Rs 3,500) and 5mg (Rs 4,375) doses. It will be available only via prescription.

Mounjaro mimics the body’s GIP and GLP-1 hormones, aiding in blood sugar control and weight loss. Doctors describe it as a significant advancement over previous anti-obesity medications, which often proved ineffective or unsustainable. Similar to Novo Nordisk’s Ozempic, it stimulates insulin release and delays stomach emptying, leading to increased satiety and reduced appetite.

While hailed as a major step forward in managing type 2 diabetes and obesity, Dr. Ambrish Mithal, Chairman & Head of Endocrinology & Diabetes at Max Healthcare, stressed the importance of responsible use. He cautioned against casual use and emphasized that the drug should only be taken under strict medical supervision from an endocrinologist or physician. Dr. Monica Mahajan, Director of Internal Medicine at Max Healthcare, further explained the mechanism of action, highlighting its multi-system influence for effective management of both diabetes and weight.

The launch comes amid rising obesity rates in India, which contribute significantly to the prevalence of diabetes, heart disease, and other related conditions. Dr. Mithal advocates for a focus on preventative measures, promoting healthy eating habits from a young age. The accessibility of Mounjaro at a comparatively more affordable price in India, compared to international markets, is seen as a positive development for patients.

Read More